Drug Type Monoclonal antibody |
Synonyms Anti-KDR mAb, Anti-VEGFR-2-mAb-PharmAbcine, Fully human monoclonal antibody targets vascular endothelial growth factor receptor 2 + [4] |
Target |
Mechanism VEGFR2 antagonists(Vascular endothelial growth factor receptor 2 antagonists), Angiogenesis inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
RegulationOrphan Drug (US) |
Start Date30 Sep 2021 |
Sponsor / Collaborator PharmAbcine Inc. [+1] |
Start Date13 Nov 2019 |
Sponsor / Collaborator |
Start Date16 Jan 2019 |
Sponsor / Collaborator |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Recurrent Glioblastoma | Phase 2 | - | 04 Feb 2016 | |
Triple Negative Breast Cancer | Phase 1 | AU | 03 Jan 2019 | |
Recurrent Glioblastoma | Discovery | - | 04 Feb 2016 | |
Advanced cancer | Discovery | KR | 01 Nov 2011 |
Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
---|
NCT03722342 (ASCO2020) Manual | Phase 1 | 9 | olinvacimab+pembrolizumab | (hohfjiyqrg) = blurred vision, fatigue, and seizure gqimgsnbqs (fpxbcrboqw ) View more | Positive | 29 May 2020 | |
NCT03033524 (ASCO2017) Manual | Phase 2 | 12 | (xrqxspbknu) = All SAEs were unrelated to the study drug apart from G2 bleeding haemangioma and G2 cerebral haemorrhage. doznkzukwu (edsbdojhrt ) | Positive | 02 Jun 2017 | ||
Phase 1 | 26 | (rjxzhzocvk) = kgwzmovdrb dcdcoukykd (wtbfajhevv ) View more | - | 20 May 2015 |